Ecallantide (Kalbitor)

Ecallantide (Kalbitor) is covered only for treatment of acute HAE attacks in patients with HAE type I or II due to C1‑INH deficiency (not covered for HAE with normal C1‑INH, prophylaxis, or other off‑label uses). Key requirements: baseline labs showing functional C1‑INH <50% and low serum C4, prescription by or in consultation with an allergist/immunologist or HAE specialist, approvals for 12 months with reauthorization requiring prior Kalbitor use and documented favorable clinical response, and dosing limited to ≤30 mg subcutaneously no more than twice daily.

"Kalbitor is indicated for the treatment of acute Hereditary Angioedema (HAE) attacks."

Sign up to see full coverage criteria, indications, and limitations.